BioAtla, Inc. (NASDAQ:BCAB) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its position in BioAtla, Inc. (NASDAQ:BCAB) by 62.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 829,596 shares of the company’s stock after buying an additional 318,196 shares during the quarter. Renaissance Technologies LLC owned 1.72% of BioAtla worth $490,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BCAB. Magnus Financial Group LLC purchased a new position in BioAtla in the fourth quarter valued at about $28,000. Norges Bank acquired a new position in shares of BioAtla in the 4th quarter valued at approximately $230,000. Finally, Highbridge Capital Management LLC purchased a new position in shares of BioAtla during the 4th quarter valued at approximately $1,484,000. 77.23% of the stock is owned by hedge funds and other institutional investors.

BioAtla Stock Performance

NASDAQ:BCAB opened at $0.56 on Friday. The stock has a 50-day simple moving average of $0.35 and a 200 day simple moving average of $0.85. BioAtla, Inc. has a one year low of $0.24 and a one year high of $3.42. The company has a market capitalization of $32.59 million, a price-to-earnings ratio of -0.33 and a beta of 1.08.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. On average, equities research analysts forecast that BioAtla, Inc. will post -1.46 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of BioAtla in a report on Monday, March 31st.

BioAtla Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.